- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03444805
EBMT ADWP Prospective Non-interventional Study: Post-AHSCT Management in SSC Patients (NISSC-2) (NISSC-2)
Post-AHSCT (Autologous Hematopoietic Stem Cell Transplantation) Management for Patients With Systemic Sclerosis: a Prospective, Non-interventional Approach Across Europe (NISSC-2) for the Autoimmune Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
NISSc-2 is a prospective observational study specifically designed to assess the effectiveness of various post-transplant treatment management approaches on clinical and immune biological responses after Autologous Hematopoietic Stem Cell transplantation (AHSCT) for Systemic Sclerosis (SSc) as currently performed by the different treatment protocols used in routine clinical practice across Europe in various EBMT centres through the careful recording and analysis of routinely collected clinical and immune biological data, and specific data regarding post-transplant use of SSc active treatments, including:
- Steroids,
- SSc active treatments after AHSCT such as mycophenolate mofetil (MMF), azathioprine, cyclophosphamide (oral or IV), methotrexate, polyclonal antibodies (such as ATG) or monoclonal antibodies (rituximab, belimumab or any others) as well as their respective dosage and duration of each treatment. These post-transplant treatments can be administered for various reasons, which can be specified by local investigators, such as per local protocol decision for maintenance therapy, or for disease progression with or without prior clinical response, during routine clinical follow-up. Patients who do not receive any post-transplant therapy will also be observed.
Different protocols are used in the different centres, but it is not yet clear, which approach will be the most efficient and the safest. The role of stem cell purification with CD34-selection also needs to be determined prospectively.
In addition, the EBMT Autoimmune Diseases and Immunobiology Working Parties developed and implemented guidelines for 'good laboratory practice' in relation to procurement, processing, storage and analysis of biological specimens for immune reconstitution studies in AD patients before, during and after AHSCT [16]. To follow post-transplant immune reconstitution according to ADWP GCP, results of routine analyses performed by centres under standardized conditions on available biological samples will be investigated in correlation to clinical outcome parameters. Every centre will follow its own local protocol for AHSCT, which usually refers to the recent update of the EBMT guidelines for AHSCT in autoimmune disease.
We therefore specifically designed NISCC-II to prospectively capture various post-ASHCT management protocols and their effect on the observed clinical response after AHSCT.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Manuela Badoglio, MS
- Phone Number: +33 1 70 64 24 16
- Email: manuela.badoglio@upmc.fr
Study Contact Backup
- Name: Dominique Farge, PhD
- Email: dominique.farge-bancel@aphp.fr
Study Locations
-
-
-
Paris, France, 75010
- Recruiting
- Badoglio Manuela- EBMT Paris Office
-
Contact:
- Manuela Badoglio
- Phone Number: +33.1.70.64.24.16
- Email: manuela.badoglio@upmc.fr
-
Contact:
- Dominique Farge, PhD
- Phone Number: +33 (0)1 40 27 46 13
- Email: dominique.farge-bancel@sls.aphp.fr
-
Principal Investigator:
- Dominique Farge, PhD
-
Sub-Investigator:
- Joerg Henes, MD
-
Sub-Investigator:
- Hans Ulrich Scherer, PhD
-
Sub-Investigator:
- John A Snowden, PhD
-
Sub-Investigator:
- Nicoletta Del Papa, PhD
-
Sub-Investigator:
- John Moore, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- - Autologous HSCT
- - Age above 18 years at time of transplant.
- -. Established diagnosis of progressive SSc according to 2013 ACR/EULAR classification criteria
Exclusion Criteria:
- Pregnancy or inadequate contraception
- Severe concomitant disease
Reduced lung, cardiac or renal function
a. .Reduced lung function with FVC < 50% or DLCO < 30% (of predicted values) b; .Pulmonary arterial hypertension with baseline (resting) PASP > 40 mmHg or mPAP > 25 mmHg or a PASP > 45 mmHg or mPAP > 30 mmHg after fluid challenge or Pulmonary vascular resistance > 3 Wood units on RHC c. Severe heart failure with Ejection Fraction < 45% by cardiac echocardiography d. D-sign of septal bounce on cardiac MRI e. Unrevascularized severe coronary artery disease f. Untreated severe arrhythmia g. Cardiac tamponade h. Constrictive pericarditis i. Kidney insufficiency: creatinine clearance <30ml/min Previously damaged bone marrow
- Leukopenia < 2.0 x 109/L (total white cell count)
- Thrombocytopenia < 100 x 109/L
- Uncontrolled severe or chronic infection (Hepatitis B/C, HIV, Salmonella carrier, syphilis, tuberculosis)
- Severe concomitant psychiatric illness (depression, psychosis)
- Concurrent neoplasms or myelodysplasia in the past 5 years
- Smoking (current)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
NISSC-2
SSC patients treated with AHSCT
|
1st AHSCT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS),
Time Frame: 2 years post transplant
|
defined as survival since AHSCT without evidence of progression of SSc.
|
2 years post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment related toxicity
Time Frame: 100 days post-transplant
|
Treatment related toxicity throughout the study period using WHO toxicity parameters (expressed as maximum grade toxicity per organ system, see appendix) Incidence of Adverse Events (AE) and Serious Adverse Events (SE) Neutrophil and platelet engraftment, defined as first day after transplantation with absolute neutrophil count > 0.5 x 109/L and platelet count >20 x 109/L (without platelet transfusion).
|
100 days post-transplant
|
100 days Treatment Related Mortality (100d TRM)
Time Frame: 100 days post-transplant
|
defined as any death during 100 days following transplant that cannot be attributed to progression or relapse of the disease
|
100 days post-transplant
|
Overall Survival (OS)
Time Frame: 2 years post-transplant
|
Overall survival
|
2 years post-transplant
|
Use of prednisone equivalent
Time Frame: 1 year and 2 years post-transplant
|
Use of prednisolone equivalent > 6 mg/day for more than 3 months
|
1 year and 2 years post-transplant
|
Use of immunosuppressive drugs
Time Frame: 2 years post-transplant
|
defined as use of any post-transplant immunosuppressive drugs (mycophenolate mofetil, azathioprine, oral or iv cyclosphosphamide or methotrexate) for either causes (maintenance therapy as per local protocol decision, SSc progression or relapse) and total duration of exposure to this post-transplant immunosuppressive treatment (average monthly daily dose and months duration)
|
2 years post-transplant
|
Use of post-transplant biotherapies
Time Frame: 2 years post-transplant
|
defined as use of any monoclonal (i.e.
anti CD20, anti-BLyS, alemtuzumab or polyclonal (i.e.
ATG) antibodies for either causes (per local protocol decision, EBV infection or reactivation, progression or relapse) and total doses (in number and g/kg)
|
2 years post-transplant
|
Response to treatment
Time Frame: 1 year and 2 years post-transplant
|
defined as any of the following changes
|
1 year and 2 years post-transplant
|
Infectious complications, CMV / EBV reactivation
Time Frame: 2 years post-transplant
|
Infectious complications, CMV / EBV reactivation
|
2 years post-transplant
|
Secondary autoimmune diseases and secondary malignancy
Time Frame: 2 years post-transplant
|
defined, autoimmune thrombocytopaenia, autoimmune thyroid disease, autoimmune haemolytic anaemia, Evans' syndrome, acquired haemophila, ulcerative colitis, rheumatoid arthritis and spondyloarthropathy, autoimmune hepatitis, others) and secondary malignancy (EBV lymphoproliferative disorders, AML, MDS, skin cancers, and any others
|
2 years post-transplant
|
Immune reconstitution
Time Frame: 2 years post-transplant
|
Results of routine analysis performed by centres will be investigated in correlation to clinical outcomes parameters and will allow to follow post-transplant immune reconstitution according to ADWP GCP.
|
2 years post-transplant
|
Collaborators and Investigators
Investigators
- Study Chair: Dominique Farge, PhD, EBMT ADWP
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADWP 8410025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Diseases
-
SanofiRecruitingHealthy Volunteers | Autoimmune DisorderUnited States
-
National Eye Institute (NEI)Completed
-
The Eye Center and The Eye Foundation for Research...CompletedAutoimmune Polyglandular Syndrome Type I | Autoimmune Keratitis
-
Sinocelltech Ltd.Not yet recruiting
-
TakedaCompletedAutoimmune DiseaseUnited Kingdom
-
Ziv HospitalUnknownAutoimmune DiseaseIsrael
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
Muğla Sıtkı Koçman UniversityCompletedMultiple Sclerosis | Telerehabilitation | Autoimmune Disorder | Exercise ProgramTurkey
-
Fundación Pública Andaluza Progreso y SaludKarolinska Institutet; Eli Lilly and Company; Medical University of Vienna; Sanofi and other collaboratorsCompletedSystemic Autoimmune DiseasesFrance, Belgium, Germany, Italy, Spain, Switzerland
-
Ruijin HospitalRecruiting
Clinical Trials on Autologous HSCT
-
European Society for Blood and Marrow TransplantationCompletedAutoimmune DiseasesFrance
-
National Research Center for Hematology, RussiaUnknownPrecursor Cell Lymphoblastic Leukemia-LymphomaRussian Federation
-
Nanfang Hospital, Southern Medical UniversityZhujiang HospitalCompletedAcute Myeloid Leukemia | Risk Stratification
-
Gary A Levy, O. Ont. MD. FRCP AGAFOttawa Hospital Research InstituteCompletedComplication of Transplanted Organ, NosCanada
-
National Research Center for Hematology, RussiaUnknownPh-negative Adult Acute Lymphoblastic LeukemiaRussian Federation
-
Beijing GoBroad HospitalRecruitingRefractory/Relapsed Acute Myeloid LeukaemiaChina
-
Beijing GoBroad HospitalRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic LeukemiaChina
-
Ottawa Hospital Research InstituteMultiple Sclerosis Scientific Research FoundationCompleted
-
UMC UtrechtBoehringer Ingelheim; ZonMw: The Netherlands Organisation for Health Research... and other collaboratorsRecruitingSystemic Sclerosis | Scleroderma, Diffuse | Mycophenolate Mofetil | Scleroderma | Autologous Stem Cell Transplantation | Cyclophosphamide | Systemic Scleroses, Diffuse | Treatment StrategyItaly, Switzerland, Netherlands, Sweden, United Kingdom
-
Federal Research Institute of Pediatric Hematology...Physicians, Innovations, Science for Children FundRecruitingAcute Myeloid Leukemia, ChildhoodRussian Federation